A series of patients (altogether 18) was treated in 1990 for the recurrence of glioma by injecting [211At]At-labelled anti-tenascin molecule directly into the tumour cavity; time to progression was superior to the reports from the literature, including no physiological side effects [99]. This evidence concerns the gene TNC and central nervous system cancer.